Is Prism Medico overvalued or undervalued?

As of 17 November 2025, Prism Medico's valuation grade has moved from fair to very attractive, indicating a significant improvement in its perceived value. The company is currently considered undervalued, especially when compared to its peers. Key ratios include a PE ratio of 18.90, an EV to EBIT of 11.46, and a Price to Book Value of 0.76, which suggest that the stock is trading at a discount relative to its earnings and assets.
In comparison to peers, Prism Medico's PE ratio is notably lower than Apollo Hospitals at 64.41 and Max Healthcare at 77.22, both of which are classified as very expensive. This reinforces the notion that Prism Medico offers a more attractive investment opportunity. Despite recent underperformance against the Sensex, with a year-to-date return of -21.45% compared to the Sensex's 8.72%, the company's valuation metrics suggest it is well-positioned for potential recovery and growth.